Stockreport

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer [Yahoo! Finance]

ALX Oncology Holdings Inc.  (ALXO) 
PDF with heavily pretreated HER2-positive breast cancer who had received multiple HER2-targeted agents, including fam-trastuzumab deruxtecan-nxki (ENHERTU ® Combination th [Read more]